STAT3 and lung carcinoma: On drug resistance, crizotinib inhibited cytoplasmic STAT3, led to EIF2A phosphorylation, then inhibited nuclear STAT3, and then downregulated B-cell lymphoma gene-2 (BCL-2), and finally led to a high level of protective autophagy in lung cancer cells (6).